Morote J - Search Results

1

Molecular markers for prostate cancer in formalin-fixed paraffin-embedded tissues.

Sequeiros T, García M, Montes M, Oliván M, Rigau M, Colás E, de Torres I, Morote J, Reventós J, Doll A. Sequeiros T, et al. Among authors: morote j. Biomed Res Int. 2013;2013:283635. doi: 10.1155/2013/283635. Epub 2013 Nov 25. Biomed Res Int. 2013. PMID: 24371818 Free PMC article. Review.

2

The percentage of free prostatic-specific antigen is also useful in men with normal digital rectal examination and serum prostatic-specific antigen between 10.1 and 20 ng/ml.

Morote J, Trilla E, Esquena S, Serrallach F, Abascal JM, Muñoz A, Id M'Hammed Y, de Torres IM. Morote J, et al. Eur Urol. 2002 Oct;42(4):333-7. doi: 10.1016/s0302-2838(02)00318-4. Eur Urol. 2002. PMID: 12361897

3

PTOV-1, a novel protein overexpressed in prostate cancer, shuttles between the cytoplasm and the nucleus and promotes entry into the S phase of the cell division cycle.

Santamaría A, Fernández PL, Farré X, Benedit P, Reventós J, Morote J, Paciucci R, Thomson TM. Santamaría A, et al. Among authors: morote j. Am J Pathol. 2003 Mar;162(3):897-905. doi: 10.1016/S0002-9440(10)63885-0. Am J Pathol. 2003. PMID: 12598323 Free PMC article.

4

Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer.

Morote J, Trilla E, Esquena S, Abascal JM, Reventos J. Morote J, et al. Int J Cancer. 2004 Mar 1;108(6):877-81. doi: 10.1002/ijc.11639. Int J Cancer. 2004. PMID: 14712491

5

PTOV1 enables the nuclear translocation and mitogenic activity of flotillin-1, a major protein of lipid rafts.

Santamaría A, Castellanos E, Gómez V, Benedit P, Renau-Piqueras J, Morote J, Reventós J, Thomson TM, Paciucci R. Santamaría A, et al. Among authors: morote j. Mol Cell Biol. 2005 Mar;25(5):1900-11. doi: 10.1128/MCB.25.5.1900-1911.2005. Mol Cell Biol. 2005. PMID: 15713644 Free PMC article.

6

Effect of androgen deprivation therapy in the thyroid function test of patients with prostate cancer.

Morote J, Esquena S, Orsola A, Salvador C, Trilla E, Cecchini L, Raventós CX, Planas J, Catalán R, Reventós J. Morote J, et al. Anticancer Drugs. 2005 Sep;16(8):863-6. doi: 10.1097/01.cad.0000173474.82486.74. Anticancer Drugs. 2005. PMID: 16096434

7

Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression.

Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J. Morote J, et al. J Urol. 2006 May;175(5):1679-83; discussion 1683. doi: 10.1016/S0022-5347(05)00999-7. J Urol. 2006. PMID: 16600728

8

Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.

Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Raventós CX, Catalán R, Reventós J. Morote J, et al. Urol Int. 2006;77(2):135-8. doi: 10.1159/000093907. Urol Int. 2006. PMID: 16888418

9

Case report: retroperitoneal fibrosis simulating local relapse of sarcomatoid renal cell carcinoma.

Esquena S, Abascal JM, Trilla E, De Torres I, Morote J. Esquena S, et al. Among authors: morote j. Int Urol Nephrol. 2006;38(3-4):463-5. doi: 10.1007/s11255-006-6653-8. Int Urol Nephrol. 2006. PMID: 17146608

10

Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer.

Morote J, Morin JP, Orsola A, Abascal JM, Salvador C, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J. Morote J, et al. Urology. 2007 Mar;69(3):500-4. doi: 10.1016/j.urology.2006.11.002. Urology. 2007. PMID: 17382153

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

299 results

Search Page

Filters